Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | October 25, 2005 | ||||
| Last Updated Date | February 25, 2012 | ||||
| Start Date ICMJE | October 2005 | ||||
| Primary Completion Date | December 2011 (final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures ICMJE |
|
||||
| Original Primary Outcome Measures ICMJE |
|
||||
| Change History | Complete list of historical versions of study NCT00244673 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE |
|
||||
| Original Secondary Outcome Measures ICMJE |
|
||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination | ||||
| Official Title ICMJE | Diphteria-tetanus-pertussis (DTP) Vaccination and Child Survival: Randomized Study of Not Providing DTP Vaccination Together With or After Measles Vaccination | ||||
| Brief Summary | In non-randomized studies, routine childhood vaccinations have been observed to have non-targeted effects. Difteria-tetanus-pertussis (DTP) vaccine provided with or after measles vaccine (MV) is associated with increased mortality in areas with herd immunity to pertussis. We will examine in a randomised study of 6000 children the effect of not administering DTP simultaneously with or after MV on overall child mortality, hospitalization rates, and the immunological responses after vaccination. We will also examine potential sex-differential effects in the outcomes and interactions with other vaccines, other health interventions and season. |
||||
| Detailed Description | Background: Infectious diseases are the main cause of high child mortality in Africa. In several non-randomised studies, routine childhood vaccinations have been observed to have non-targeted effects. Live vaccines like measles vaccine (MV) seem to protect against overall mortality, whereas killed vaccines, like DTP, may have no beneficial effects, especially for girls. DTP provided with or after MV may be associated with increased mortality. The mechanisms behind these effects are unknown. Hypothesis: Not providing DTP together with or after MV is associated with a 35 % reduction in overall mortality and 23% reduction in hospitalizations. Objectives: To examine in a randomised study of 6000 children the effect of not administering DTP simultaneously with or after MV on
Methods: Surveillance system: BHP's demographic surveillance system in Bissau covers 6 districts with a population of 90,000; 3,500 children are born each year. Hospitalizations: There is only one pediatric ward in Bissau and all hospitalizations are identified in the BHP register. Vaccinations: Vaccinations are provided and registered at the 3 health centres in the study area. Intervention: In this study 6000 children are randomised as they come to receive DTP3 or DTP booster with or after measles vaccination (MV) at the local health centres. Children will be randomised to DTP3+OPV3 and MV versus OPV3 and MV or DTP4+OPV4 versus OPV4 (booster doses). Follow-up: The children will be followed until 4 years of age or end of study.
Sample size: With a total of 7500 person-years of follow-up, we will be able to document a 35% reduction in mortality and a 23% reduction in hospitalizations. A subgroup of children will be examined for possible differences in immunological profile after vaccination. Ethical considerations: Herd immunity to pertussis should not be affected as, due to the intervention, more children is vaccinated. |
||||
| Study Type ICMJE | Interventional | ||||
| Study Phase | Phase 4 | ||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label |
||||
| Condition ICMJE |
|
||||
| Intervention ICMJE | Biological: DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4
Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age. |
||||
| Study Arm (s) | Not Provided | ||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Completed | ||||
| Enrollment ICMJE | 6534 | ||||
| Completion Date | December 2011 | ||||
| Primary Completion Date | December 2011 (final data collection date for primary outcome measure) | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria: Normally applied contraindications for receiving vaccinations, including high fever |
||||
| Gender | Both | ||||
| Ages | 9 Months to 4 Years | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | Guinea-Bissau | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT00244673 | ||||
| Other Study ID Numbers ICMJE | CVEK2005-7041-45-DTPMV, CVEK2005-7041-45 | ||||
| Has Data Monitoring Committee | Not Provided | ||||
| Responsible Party | Bandim Health Project | ||||
| Study Sponsor ICMJE | Bandim Health Project | ||||
| Collaborators ICMJE |
|
||||
| Investigators ICMJE |
|
||||
| Information Provided By | Bandim Health Project | ||||
| Verification Date | February 2012 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||